FREEZE-DRIED BINARY AND TERNARY SOLID DISPERSIONS OF CANNABIDIOL: FORMULATION, CHARACTERIZATION, AND SOLUBILITY ENHANCEMENT
DOI:
https://doi.org/10.22159/ijap.2026v18i4.58197Keywords:
Cannabidiol, Solid dispersion, Freeze-drying, Solubility enhancement, Amorphous systemAbstract
Objective: Cannabidiol (CBD) is a non-psychoactive phytocannabinoid with broad therapeutic potential. However, its extremely poor aqueous solubility limits pharmaceutical development. This study aimed to enhance CBD solubility using binary and ternary amorphous solid dispersions (SDs) prepared by freeze-drying.
Methods: Freeze-drying conditions were optimized by screening solvent systems based on frozen-state thermal behavior. Binary SDs were prepared with polyvinylpyrrolidone (PVP-K30 or PVP-K90), while ternary SDs incorporated surfactants (TPGS, poloxamer 188, and poloxamer 407). Formulations were evaluated for solubility, dissolution, solid-state properties (DSC, FTIR), and stability.
Results: The optimal solvent system was 35% (v/v) tert-butyl alcohol. Binary SDs increased CBD solubility by up to 32-fold. Initial screening of ternary systems achieved approximately 7,000-fold enhancement, with poloxamer 407 showing the greatest effect. Further optimization yielded formulations (F7 and F14) with up to ~11,000-fold increased solubility and rapid dissolution. DSC confirmed complete amorphization, while FTIR indicated intermolecular interactions. The optimized formulations maintained amorphous characteristics and >96% CBD content after six months.
Conclusion: Freeze-dried ternary SDs, particularly those containing poloxamer 407, provide a robust strategy for markedly enhancing CBD solubility and dissolution with good stability.
References
1. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9(1):21. doi: 10.3390/antiox9010021, PMID 31881765.
2. Cásedas G, Yarza-Sancho MD, López V. Cannabidiol (CBD): a systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals (Basel). 2024;17(11):1438. doi: 10.3390/ph17111438, PMID 39598350.
3. Freeman TP, Hindocha C, Green SF, Bloomfield MA. Medicinal use of cannabis-based products and cannabinoids. BMJ. 2019;365:l1141. doi: 10.1136/bmj.l1141, PMID 30948383.
4. Koch N, Jennotte O, Gasparrini Y, Vandenbroucke F, Lechanteur A, Evrard B. Cannabidiol aqueous solubility enhancement: comparison of three amorphous formulations strategies using different type of polymers. Int J Pharm. 2020;589:119812. doi: 10.1016/j.ijpharm.2020.119812, PMID 32882367.
5. Nakano Y, Tajima M, Sugiyama E, Sato VH, Sato H. Development of a novel nano-emulsion formulation to improve intestinal absorption of cannabidiol. Med Cannabis Cannabinoids. 2019;2(1):35-42. doi: 10.1159/000497361, PMID 34676332.
6. Leibtag S, Peshkovsky A. Cannabis extract nanoemulsions produced by high-intensity ultrasound: formulation development and scale-up. J Drug Delivery Sci Technol. 2020;60:101953. doi: 10.1016/j.jddst.2020.101953.
7. Banerjee A, Binder J, Salama R, Trant JF. Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion. J Cannabis Res. 2021;3(1):43. doi: 10.1186/s42238-021-00094-w.
8. Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. Molecules. 2019;24(16):2967. doi: 10.3390/molecules24162967, PMID 31426272.
9. Taha IE, ElSohly MA, Radwan MM, Elkanayati RM, Wanas A, Joshi PH, et al. Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: in vitro and in vivo evaluation studies. Drug Delivery Transl Res. 2025:15(8):2722–32. doi: 10.1007/s13346-024-01766-9.
10. Wang TY, Liu M, Portincasa P, Wang DQH. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest. 2013;43(11):1203–23. doi: 10.1111/eci.12161, PMID 24102389.
11. Shirke SH, Shewale SB, Kulkarni AS, Aloorkar NH. Solid dispersion: a novel approach for poorly water soluble drugs. Int J Curr Pharm Res. 2015;7(4):1–8.
12. Guntaka PR, Lankalapalli S. Solid dispersion – a novel approach for bioavailability enhancement of poorly water-soluble drugs in solid oral dosage forms. Asian J Pharm Clin Res. 2019;12(2):17–26. doi: 10.22159/ajpcr.2019.v12i2.29157.
13. Jennotte O, Koch N, Lechanteur A, Evrard B. Development of amorphous solid dispersions of cannabidiol: influence of the carrier, the hot-melt extrusion parameters and the use of a crystallization inhibitor. J Drug Deliv Sci Technol. 2022;71:103372. doi: 10.1016/j.jddst.2022.103372.
14. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008;97(4):1329–49. doi: 10.1002/jps.21138, PMID 17722100.
15. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics. 2019;11(3):132. doi: 10.3390/pharmaceutics11030132, PMID 30893899.
16. Zhang Z, Dong L, Guo J, Li L, Tian B, Zhao Q, et al. Prediction of the physical stability of amorphous solid dispersions: relationship of aging and phase separation with the thermodynamic and kinetic models along with characterization techniques. Expert Opin Drug Delivery. 2020;18(2):249–64. doi: 10.1080/17425247.2021.1844181, PMID 33112679.
17. Saboo S, Bapat P, Moseson DE, Kestur US, Taylor LS. Exploring the role of surfactants in enhancing drug release from amorphous solid dispersions at higher drug loadings. Pharmaceutics. 2021;13(5):735. doi: 10.3390/pharmaceutics13050735, PMID34067666.
18. Budiman A, Lailasari E, Nurani NV, Yunita EN, Anastasya G, Aulia RN, et al. Ternary solid dispersions: a review of the preparation, characterization, mechanism of drug release, and physical stability. Pharmaceutics. 2023;15(8):2116. doi: 10.3390/pharmaceutics15082116, PMID 37631330.
19. Koga K, Yoshizumi H. Differential scanning calorimetry (DSC) studies on the structures of water‐ethanol mixtures and aged whiskey. J Food Sci. 1977;42(5):1213–7. doi: 10.1111/j.1365-2621.1977.tb14462.x.
20. Fitriani L, Haqi A, Zaini E. Preparation and characterization of solid dispersion freeze-dried efavirenz – polyvinylpyrrolidone K-30. J Adv Pharm Technol Res. 2016;7(3):105–9. doi: 10.4103/2231-4040.184592. PMID: 27429930; PMCID: PMC4932804.
21. Jaidee W, Siridechakorn I, Nessopa S, Wisuitiprot V, Chaiwangrach N, Ingkaninan K, et al. Kinetics of CBD, Δ9-THC degradation and cannabinol formation in cannabis resin at various temperature and pH conditions. Cannabis Cannabinoid Res. 2022;7(4):537–47. doi: 10.1089/can.2021.0004, PMID 34096805.
22. Sapkal SB, Adhao VS, Thenge RR, Darakhe RA, Shinde SA, Shrikhande VN. Formulation and characterization of solid dispersions of etoricoxib using natural polymers. Turk J Pharm Sci. 2020;17(1):7–19. doi: 10.4274/tjps.galenos.2018.04880, PMID 32454755.
23. Almeida H, Ferreira B, Fernandes-Lopes C, Araújo F, Bonifácio MJ, Vasconcelos T, et al. Third-generation solid dispersion through lyophilization enhanced oral bioavailability of resveratrol. ACS Pharmacol Transl Sci. 2024;7(3):888–98. doi:10.1021/acsptsci.4c00029.
24. Possenti E, Colombo C, Realini M, Song CL, Kazarian SG. Time-resolved ATR-FTIR spectroscopy and macro ATR-FTIR spectroscopic imaging of inorganic treatments for stone conservation. Anal Chem. 2021;93(44):14635–42. doi: 10.1021/acs.analchem.1c02392, PMID 34699174.
25. Bruel C, Queffeulou S, Darlow T, Virgilio N, Tavares JR, Patience GS. Experimental methods in chemical engineering: contact angles. Can J Chem Eng. 2019;97(4):832–42. doi: 10.1002/cjce.23408.
26. Yuan Y, Lee TR. Contact angle and wetting properties. In: Bracco G, Holst B, editors. Surface science techniques. Springer Series in Surface Sciences. Berlin, Heidelberg: Springer; 2013. p. 3–34. doi: 10.1007/978-3-642-34243-1_1.
27. Luo Y, Hong Y, Shen L, Wu F, Lin X. Multifunctional role of polyvinylpyrrolidone in pharmaceutical formulations. AAPS PharmSciTech. 2021;22(1):34. doi: 10.1208/s12249-020-01909-4, PMID 33404984.
28. Rusdin A, Mohd Gazzali A, Ain Thomas N, Megantara S, Aulifa DL, Budiman A, et al. Advancing drug delivery paradigms: polyvinyl pyrrolidone (PVP)-based amorphous solid dispersion for enhanced physicochemical properties and therapeutic efficacy. Polymers. 2024;16(2):286. doi: 10.3390/polym16020286, PMID 38276694.
29. Ha ES, Choo GH, Baek IH, Kim MS. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process. Molecules. 2014;19(12):20325–39. doi: 10.3390/molecules191220325, PMID 25486246.
30. Kapourani A, Tzakri T, Valkanioti V, Kontogiannopoulos KN, Barmpalexis P. Drug crystal growth in ternary amorphous solid dispersions: effect of surfactants and polymeric matrix-carriers. Int J Pharm X. 2021;3:100086. doi: 10.1016/j.ijpx.2021.100086.
31. Knopp MM, Nguyen JH, Becker C, Francke NM, Jørgensen EB, Holm P, et al. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib: PVP amorphous solid dispersions. Eur J Pharm Biopharm. 2016;101:145–51. doi: 10.1016/j.ejpb.2016.02.007.
32. Dontireddy R, Crean AM. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions. Drug Dev Ind Pharm. 2011;37(10):1141–9. doi: 10.3109/03639045.2011.562213.
33. Kunz C, Gieseler H. Factors influencing the retention of organic solvents in products freeze-dried from co-solvent systems. J Pharm Sci. 2018;107(8):2005–12. doi: 10.1016/j.xphs.2018.04.001, PMID 29649470.
34. Tchessalov S, Maglio V, Kazarin P, Alexeenko A, Bhatnagar B, Sahni E, et al. Practical advice on scientific design of freeze-drying process: 2023 update. Pharm Res. 2023;40(10):2433–55. doi: 10.1007/s11095-023-03607-9, PMID 37783925.
35. Kittaka S, Kuranishi M, Ishimaru S, Umahara O. Phase separation of acetonitrile-water mixtures and minimizing of ice crystallites from there in confinement of MCM-41. J Chem Phys. 2007;126(9):091103. doi: 10.1063/1.2712432.
36. Vessot S, Andrieu J. A review on freeze drying of drugs with tert-butanol (TBA) + water systems: characteristics, advantages, drawbacks. Drying Technol. 2012;30(4):377–85. doi: 10.1080/07373937.2011.628133.
37. Cerar J, Jamnik A, Pethes I, Temleitner L, Pusztai L, Tomšič M. Structural, rheological and dynamic aspects of hydrogen-bonding molecular liquids: aqueous solutions of hydrotropic tert-butyl alcohol. J Colloid Interface Sci. 2020;560:730–42. doi: 10.1016/j.jcis.2019.10.094, PMID 31704003.
38. Bhatnagar BS, Sonje J, Shalaev E, Martin SW, Teagarden DL, Suryanarayanan R. A refined phase diagram of the tert-butanol–water system and implications on lyophilization process optimization of pharmaceuticals. Phys Chem Chem Phys. 2020;22(3):1583–90. doi: 10.1039/C9CP06576H, PMID 31894786.
39. International Council for Harmonisation (ICH). ICH guideline Q2(R2): validation of analytical procedures. Geneva: ICH; 2022. Available from: https://www.ich.org. [Last accessed on 2026 Jan 10].
40. Cherif A, Deshmukh J, Sanil K, Taha I, Treffer D, Ashour EA. Towards enhanced solubility of cannabidiol: preparation and evaluation of cannabidiol solid dispersions using vacuum compression molding. AAPS PharmSciTech. 2025;26(3):83. doi: 10.1208/s12249‑025‑03078‑8.
41. Andriotis EG, Chachlioutaki K, Monou PK, Bouropoulos N, Tzetzis D, Barmpalexis P, et al. Development of water-soluble electrospun fibers for the oral delivery of cannabinoids. AAPS PharmSciTech. 2021;22(1):23. doi:10.1208/s12249‑020‑01895‑7, PMID33400042.
42. Zhang Z, Tan S, Feng S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889–906. doi: 10.1016/j.biomaterials.2012.03.046, PMID 22498300.
43. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2-3):189–212. doi: 10.1016/S0168-3659(02)00009-3, PMID 12175737.
44. Pironi AM, Eloy JdO, Rodero CF, Antonio SG, Alonso JD, Chorilli M. PVP solid dispersions containing poloxamer 407 or TPGS for the improvement of ursolic acid release. Braz J Pharm Sci. 2023;59:e21217. doi: 10.1590/s2175‑97902023e21217.
45. Ha JM, Kang SY, Park CW, Bin SA, Rhee YS, Seo JW, et al. Effect of poloxamer on physicochemical properties of tacrolimus solid dispersion improving water solubility and dissolution rate. J Pharm Invest. 2012;42:171–6. doi: 10.1007/s40005-012-0025-4.
46. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691–8. doi: 10.1023/A:1012167410376, PMID 9453055.
47. Ugur BE, Caggiano NJ, Monson S, Bechtold AG, Seo Y, Prud’homme RK, et al. Molecular interactions underlying dissolution trends in cannabidiol-polymer amorphous solid dispersions. Macromolecules. 2024;57(17):8287–97. doi: 10.1021/acs.macromol.4c01579.
48. Ministry of Public Health (Thailand). Notification of the Ministry of Public Health (No. 428) B.E. 2564 (2021) issued under the Food Act B.E. 2522: food products containing cannabis extract as an ingredient. Royal Thai Government Gazette. 2021;138(Special Issue 198 Ng):9.
Published
How to Cite
Issue
Section
Copyright (c) 2026 THANAPORN JUNTANON, NETI WARANUCH, KORNKANOK INGKANINAN, TASANA PITAKSUTEEPONG
This work is licensed under a Creative Commons Attribution 4.0 International License.